Ftse Mib
33.707,21
0,00%
DAX
18.162,53
0,00%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
61.625,52
-0,30%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ vTv Therapeutics Inc (VTVT) vTv Therapeutics Inc (VTVT) Notizie

VTVT

vTv Therapeutics (VTVT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VTVT
DataOraFonteTitoloSimboloCompagnia
14/06/202422:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
13/06/202422:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTVTvTv Therapeutics Inc
28/05/202414:00PR Newswire (US)CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETINGNASDAQ:VTVTvTv Therapeutics Inc
09/05/202422:51GlobeNewswire Inc.vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
09/05/202422:32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTVTvTv Therapeutics Inc
19/03/202413:30PR Newswire (US)CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITNASDAQ:VTVTvTv Therapeutics Inc
13/03/202413:00GlobeNewswire Inc.vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
07/03/202422:47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VTVTvTv Therapeutics Inc
07/03/202420:34Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VTVTvTv Therapeutics Inc
06/03/202401:52Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:VTVTvTv Therapeutics Inc
04/03/202414:00GlobeNewswire Inc.vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 DiabetesNASDAQ:VTVTvTv Therapeutics Inc
01/03/202414:00GlobeNewswire Inc.vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:VTVTvTv Therapeutics Inc
28/02/202415:14Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VTVTvTv Therapeutics Inc
28/02/202414:00GlobeNewswire Inc.vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundNASDAQ:VTVTvTv Therapeutics Inc
22/02/202422:00PR Newswire (US)CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCENASDAQ:VTVTvTv Therapeutics Inc
09/11/202322:30GlobeNewswire Inc.vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
08/11/202314:00GlobeNewswire Inc.vTv Therapeutics to Participate at the Stifel 2023 Healthcare ConferenceNASDAQ:VTVTvTv Therapeutics Inc
02/11/202313:00GlobeNewswire Inc.vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical OfficerNASDAQ:VTVTvTv Therapeutics Inc
01/11/202313:00GlobeNewswire Inc.vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 MillionNASDAQ:VTVTvTv Therapeutics Inc
27/09/202314:30PR Newswire (US)CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19NASDAQ:VTVTvTv Therapeutics Inc
26/09/202314:30PR Newswire (US)Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic CancerNASDAQ:VTVTvTv Therapeutics Inc
25/09/202322:20Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:VTVTvTv Therapeutics Inc
18/09/202314:30PR Newswire (US)CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMANASDAQ:VTVTvTv Therapeutics Inc
15/09/202322:17Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:VTVTvTv Therapeutics Inc
11/08/202322:30GlobeNewswire Inc.vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
10/08/202314:33PR Newswire (US)Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast CancerNASDAQ:VTVTvTv Therapeutics Inc
26/06/202322:25Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VTVTvTv Therapeutics Inc
21/06/202322:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VTVTvTv Therapeutics Inc
16/06/202314:00GlobeNewswire Inc.vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive DeclineNASDAQ:VTVTvTv Therapeutics Inc
15/06/202313:33PR Newswire (US)CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTONNASDAQ:VTVTvTv Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VTVT

La tua Cronologia

COIN
FTCCBTC
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network